High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury

Department of Internal Medicine (Cardiology), University of Michigan School of Medicine, Ann Arbor.

OBJECTIVES. The purpose of this study was to assess the anti-thrombotic potential of various forms of aspirin administration. BACKGROUND. Platelet activation in response to endothelial injury has been implicated in acute coronary syndromes. METHODS. Delivering 100-microA anodal direct current to the intima of the left circumflex coronary artery in dogs at a site of moderate external stenosis provides a thrombogenic model of vascular injury. Animals were treated with aspirin (Group I, 20 mg/kg intravenously [n = 11]; Group II, 4.6 mg/kg intravenously [n = 6]; Group III, 4.6 mg/kg orally 18 h before the experiment [n = 7]) or vehicle (Group IV, control [n = 11]). RESULTS. The time required for thrombotic occlusion to occur was longer and the incidence of thrombosis was lower in Group I (Group I, 238 +/- 7 min [n = 2]; Group II, 127 +/- 25 min [n = 3]; Group III, 156 +/- 35 min [n = 6]; Group IV, 90 +/- 11 min [n = 11]) (p < 0.05). Thrombus mass was smaller in Group I (Group I, 5.0 +/- 0.8 mg; Group II, 12.2 +/- 2.6 mg; Group III, 11.6 +/- 3.9 mg; Group IV, 9.1 +/- 1.6 mg) (p < 0.05). Initial hemodynamic variables did not differ among groups. An increase in mean arterial pressure was noted for several hours after intravenous aspirin administration in Group I (99 +/- 5 to 110 +/- 4 mm Hg) (p < 0.05). Left circumflex coronary artery blood flow was stable for 5 h in Group I (Group I, 31 +/- 2 to 26 +/- 4 ml/min) but decreased in all the other groups (Group II, 26 +/- 4 to 10 +/- 5 ml/min; Group III, 27 +/- 5 to 7 +/- 7 ml/min; Group IV, 29 +/- 4 to 0 ml/min) (p < or = 0.05). The in vivo area of left ventricle perfused by the left circumflex coronary artery was not different among groups. Platelet counts were similar and did not change over the course of the protocol. Ex vivo arachidonic acid-induced platelet aggregation decreased in all groups after aspirin (p < or = 0.001). Indium-111-labeled platelet adherence to the coronary vasculature was decreased in distal vessel segments after all doses of aspirin (p < 0.05). Platelet deposition in thrombi was similar for all treatment groups. CONCLUSIONS. High dose intravenous aspirin has salutary effects. It stabilizes left circumflex coronary artery blood flow, prolongs the time to thrombosis, reduces the incidence of thrombotic occlusion, reduces thrombus mass and limits platelet adherence to sites of arterial injury. Low dose aspirin given intravenously or orally was ineffective. When persistent intracoronary thrombi precipitate unstable coronary syndromes, high dose intravenous aspirin may be useful in the acute period even though platelets continue to interact with injured vascular segments through aspirin-insensitive mechanisms.

This article has been cited by other articles:

				G. Vilahur, E. Segales, E. Salas, and L. Badimon Effects of a Novel Platelet Nitric Oxide Donor (LA816), Aspirin, Clopidogrel, and Combined Therapy in Inhibiting Flow- and Lesion-Dependent Thrombosis in the Porcine Ex Vivo Model Circulation, September 21, 2004; 110(12): 1686 - 1693. [Abstract] [Full Text] [PDF]

				J. K. Hennan, J. Huang, T. D. Barrett, E. M. Driscoll, D. E. Willens, A. M. Park, L. J. Crofford, and B. R. Lucchesi Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries Circulation, August 14, 2001; 104(7): 820 - 825. [Abstract] [Full Text] [PDF]

				L. G. Frederick, O. D. Suleymanov, J. A. Szalony, B. B. Taite, A. K. Salyers, L. W. King, L. P. Feigen, and N. S. Nicholson Protective Effect of Oral Xemilofiban in Arterial Thrombosis in Dogs : Increased Activity in Combination With Aspirin Circulation, August 25, 1998; 98(8): 813 - 820. [Abstract] [Full Text] [PDF]

				S. Kaul, T. Z. Naqvi, M. C. Fishbein, B. Cercek, J. J. Badimon, T. C. Hutsell, S. Thomas, M. Molloy, and P. K. Shah Local Delivery of an Ultra-short-acting Nitric Oxide- releasing Compound, DMHD/NO, Is Highly Effective in Inhibiting Acute Platelet-Thrombus Formation on Injured Arterial Strips Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(3): 181 - 193. [Abstract] [PDF]

				S. Kaul, R. R. Makkar, M. Nakamura, F. I. Litvack, P. K. Shah, J. S. Forrester, T. C. Hutsell, and N. L. Eigler Inhibition of Acute Stent Thrombosis Under High-Shear Flow Conditions by a Nitric Oxide Donor, DMHD/NO: An Ex Vivo Porcine Arteriovenous Shunt Study Circulation, November 1, 1996; 94(9): 2228 - 2234. [Abstract] [Full Text]

				A. Lopez-Farre, A. Riesco, E. Digiuni, J. R. Mosquera, C. Caramelo, L. S. de Miguel, I. Millas, T. de Frutos, M. R. Cernadas, M. Monton, et al. Aspirin-Stimulated Nitric Oxide Production by Neutrophils After Acute Myocardial Ischemia in Rabbits Circulation, July 1, 1996; 94(1): 83 - 87. [Abstract] [Full Text]

				H.J.M. Barnett, M. Kaste, H. Meldrum, and M. Eliasziw Aspirin Dose in Stroke Prevention : Beautiful Hypotheses Slain by Ugly Facts Stroke, April 1, 1996; 27(4): 588 - 592. [Full Text]

				L. G. Frederick, O. D. Suleymanov, L. W. King, A. K. Salyers, N. S. Nicholson, and L. P. Feigen The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A Is Reduced When Used in Combination With Aspirin and Heparin in a Canine Model of Coronary Artery Thrombosis Circulation, January 1, 1996; 93(1): 129 - 134. [Abstract] [Full Text]

				A. Lopez-Farre, C. Caramelo, A. Esteban, M. L. Alberola, I. Millas, M. Monton, and S. Casado Effects of Aspirin on Platelet-Neutrophil Interactions : Role of Nitric Oxide and Endothelin-1 Circulation, April 1, 1995; 91(7): 2080 - 2088. [Abstract] [Full Text]